RFA-DA-24-007: Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on August 7, 2025.
From the official notice on Grants.gov, last changed October 20, 2022. Checked November 7, 2026.
- Award ceiling$300,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeDP1
- Clinical trialsNot allowed
- Funded byNIDA
- Median yearly award$462,000
- Typical project length5 years
- DP1, NIH Director's Pioneer Award. Support for an exceptionally creative scientist's high-risk, high-impact ideas. Other open DP1 notices.
Projects funded under RFA-DA-24-007 were run by National Institute on Drug Abuse (NIDA, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-24-007 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DA-23-014 | March 21, 2022 | Closed August 11, 2022 | Closed |
Key dates
| Posted | October 20, 2022 |
|---|---|
| Deadline | August 7, 2025 |
| Archived by Grants.gov | September 12, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $462,000; it allows up to $300,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.
Funded under RFA-DA-24-007 so far
NIH funded 7 projects under RFA-DA-24-007 in fiscal 2024 to 2026, at 7 institutions. The median yearly award was $462,000.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Chemical biology tools for illuminating cannabinoid signaling pathways in opioid use disorder. | Oregon Health & Science University | 2026 | $421,200 |
| Characterizing and exploiting "allosteric crosstalk" amongst pain receptors | Johns Hopkins University | 2026 | $466,363 |
| Illuminating Neuropeptide Modulation of Substance Abuse Withdrawal: Novel Photochemical Tools for Precision Control | Utah State Higher Education System--University of Utah | 2026 | $462,000 |
| Novel Mu Opioid Receptor Modulators to Counteract Synthetic Opioids | Virginia Commonwealth University | 2026 | $465,750 |
| DEVELOPING GPCR MODULATORS OF SOMATOSTATIN INTERNEURONS FOR THE TREATMENT OF OPIOID USE DISORDER | University of Pittsburgh at Pittsburgh | 2026 | $429,300 |
| A Highly Precise Platform Technology for Controlling Diverse Clinical Targets in Addiction | Vanderbilt University | 2026 | $475,500 |
| Developing Tools to Facilitate Dynamics-Based Drug Discovery of Receptors of Drugs of Abuse | Baylor College of Medicine | 2025 | $480,000 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-24-007 still open?
No. It closed on August 7, 2025.
Who can apply for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)?
Closed August 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each.
Who has been funded under RFA-DA-24-007?
NIH RePORTER lists 7 projects funded under RFA-DA-24-007 in fiscal 2024 to 2026, at 7 institutions. The most were at Oregon Health & Science University, Johns Hopkins University, Utah State Higher Education System--University of Utah.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- NIH Director's Pioneer Award (DP1 Clinical Trial Optional)
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)